The Life Science Business Series 2025

- Founders, scientists, start-ups and young companies from the fields of biotechnology, medical technology and digital health.
- Persons who are about to or in the middle of commercializing innovative technologies - whether with initial ideas or already on the way to financing, growth or exit.
- Business developers, tech transfer offices and start-up consultants who benefit from the practical insights and the exchange with experts and like-minded people.
Participation Fees
| Ticket Option | Fee | Details |
| Single Session | 65 € | Per virtual lecture (choose individually) |
| Early Bird Full Pass* | 230 € | All 5 lectures – registration until 15th October |
| Regular Full Pass* | 280 € | All 5 lectures – registration from 16th Oct - 10th Nov |
| Bonus: Campus Get-together event | Free | Registration required in advance until 12th Nov |
*Full Pass includes: access to the Campus Get-together in Martinsried, access to all lecture slides and a certificate of participation!

- Starting with a problem vs. Starting with a solution
- Scientific mindset meets entrepreneurial framing
- Role and value of incubators, accelerators & tech transfer
- Beyond the pipeline – emerging technologies and innovation models

- Market definition with Total available market (TAM), Serviceable addressable market (SAM) & Serviceable obtainable market (SOM)
- Regulatory hurdles & frameworks for biopharmaceuticals (FDA/EMA/Bfarm/PMDA/etc)
- Reimbursement strategies and timelines
- Competitor analysis and market positioning

- IP as a value driver and negotiation asset
- When to file and how to come up with an ideal strategy
- Aligning IP with funding and exit strategies
- IP models vs. Licensing models

- Types of investors & investments
- Public grants, angel funding, seed and early-stage VCs
- Non-dilutive and dilutive funding models
- Investor types and what they bring
- Cap table strategy and founder ownership
- Term sheet essentials
- Start-up valuation fundamentals

- Timing, readiness & market signals for late-stage funding
- Team structure (complementary skills and organizational structures)
- Value of experienced investors (network, advice, credibility)
- What is evaluated during due diligence?
- Different exits for investors (IPO, acquisition, failure)

- Select “Full Pass Ticket for the entire lecture series” or “Tickets for individual lectures” and confirm with a click.
- Then select again in the drop-down field how many lectures you are interested in and by ticking the boxes which specific lectures you would like to attend.
Also indicate whether you are interested in the Campus Get-together In-Person Event.
